GlassScriptPhysician profile
Erin E Beauchamp
NPI 1154674745
$1,747.28
in general payments reported to CMS, 2019-2025
23 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $513 · 2023: $326 · 2024: $328 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $384.28 | 2021-2024 | Jardiance, Zepbound |
| Dexcom, INC. | $212.85 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $170.18 | 2021-2024 | Wegovy |
| Tandem Diabetes Care, INC. | $142.66 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $104.24 | 2021-2025 | Prolia, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $101.77 | 2022 | |
| Insulet Corporation | $100.59 | 2021-2024 | Omnipod |
| Abbott Laboratories | $93.98 | 2022-2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $84.56 | 2021-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $62.73 | 2023-2024 | |
| Mannkind Corporation | $41.05 | 2023-2024 | Afrezza |
| Sequel Med Tech, LLC | $35.34 | 2025 | Twiist |
| Corcept Therapeutics | $32.79 | 2021-2025 | Korlym |
| Medtronic, INC. | $24.99 | 2023 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.88 | 2024 | Jardiance, Synjardy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $20.15 | 2022 | |
| Beta Bionics, INC. | $20.10 | 2023 | Ilet Bionic Pancreas |
| Novartis Pharmaceuticals Corporation | $18.50 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.97 | 2022 | |
| Ascensia Diabetes Care US INC. | $15.05 | 2025 | |
| Recordati_rare_diseases_inc. | $14.94 | 2021 | |
| Horizon Therapeutics Plc | $14.63 | 2023 | Tepezza |
| Cequr Corporation | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Beauchamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.